The treatment, co-developed by GSK, gained approval from the U.K’s medicines regulator after a clinical trial showed a single dose slashed the risk of hospitalisation and death by 79% in high-risk adults with symptomatic infection.
U.K. Approves Covid Antibody Treatment That’s Likely Effective Against Omicron—Here’s What To Know
